BioSpace18h
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
FierceBiotech20h
Boehringer widens fibrosis drug's approval path after boosting lung function in 2nd phase 3 trial
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Everything to know about cystic fibrosis and what causes it
Did you see this? Nearly 1 in 10 Americans have asthma. Here's what causes it.
thorax.bmj2d
Inflammation in preschool cystic fibrosis is of mixed phenotype, extends beyond the lung and is differentially modified by CFTR modulators
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Cystic fibrosis alters immune system from early life stages, researchers discover
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...